Clinical Catch-Up: January 18-22 | BioSpace
The Pharma Data
JANUARY 24, 2021
Gritstone Oncology , based in Emeryville, California, announced that it is advancing development of its own second-generation vaccine against COVID-19. CYAD-101 is the company’s allogeneic NKG2D-receptor and T cell receptor inhibitory molecule-based, non-gene edited CAR-T candidate. Read on to see. COVID-19-Related.
52 
Let's personalize your content